Drug Trial Radar · NCT04092686
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
464
Actual
Start
Oct 14, 2019
Primary completion
Jun 14, 2023
Study completion Jun 14, 2023
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Sep 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo. This study is accepting male and female participants between 18 -65 years old who have been diagnosed with schizophrenia. This study will be conducted in 60 locations world wide. The study will last up to nine (9) weeks.
Conditions
- Schizophrenia
Interventions
SEP-363856 75mgDrug
SEP-363856 75mg tablet dosed once daily
SEP-363856 100mgDrug
SEP-363856 100mg tablet dosed once daily
PlaceboDrug
Placebo tablet dosed once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in PANSS Total Score at Week 6Time frame: Baseline, Week 6
Locations
53 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Rogers, Arkansas
Research Site
Anaheim, California
Research Site
Bellflower, California
Research Site
Culver City, California
Research Site
Long Beach, California
Research Site
San Diego, California
Research Site
Sherman Oaks, California
Research Site
Hollywood, Florida
Research Site
Miami Springs, Florida
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Chicago, Illinois
Research Site
Lake Charles, Louisiana
Research Site
Gaithersburg, Maryland
Research Site
St Louis, Missouri
Research Site
Marlton, New Jersey
Research Site
New York, New York
Research Site
Richardson, Texas
Research Site
Burgas, Bulgaria
Research Site
Kardzhali, Bulgaria
Research Site
Novi Iskar, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Zagreb, Croatia
Research Site
Daugavpils, Latvia
Research Site
Riga, Latvia
Research Site
Strenči, Latvia
Research Site
Arkhangelsk, Russia
Research Site
Engel's, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saratov, Russia
Research Site
Saratov, Russia
Research Site
Stavropol, Russia
Research Site
Tomsk, Russia
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.